Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

In Review 805 articles and counting2,837 new Instagram followers1,771 new Bluesky followers It was quite a year. Join us in ...

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company reached on September 17th.

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania ...

The World Health Organization estimates that nearly 15 million people were killed either by the new coronavirus or by its impact on overwhelmed health systems during the first two years of the ...

BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

INR:9342. rover sports betting New drug for Niemann-Pick disease type C: heat shock response inducer arimoclomol applied for marketing approval Another 20 re ...

INR:8482. kerala lottery ticket guessing Hengrui's Category 3 generic drug "Glycopyrrolate Injection" is about to be approved for marketing Novarti ...

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

Biontech SE agreed to pay up to nearly $1.26 billion in two separate settlements to resolve royalty disputes with the U.S. NIH and the University of Pennsylvania related to the COVID-19 vaccine the ...